Eribulin: a novel cytotoxic chemotherapy agent (Q38012442)

27 August 2017

title

Eribulin: a novel cytotoxic chemotherapy agent (English)

1 reference

27 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

Jessica N Preston

1 reference

27 August 2017

Meghana V Trivedi

series ordinal

1 reference

27 August 2017

language of work or name

English

0 references

publication date

22 May 2012

1 reference

Annals of Pharmacotherapy

27 August 2017

1 reference

inferred from page(s)

published in

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

802-811

1 reference

The Place for Eribulin in the Treatment of Metastatic Breast Cancer

27 August 2017

cites work

1 reference

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

Macrocyclic ketone analogues of halichondrin B.

21 January 2018

1 reference

Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B

21 January 2018

1 reference

Tubulin-interactive natural products as anticancer agents

21 January 2018

1 reference

Interactions of Halichondrin B and Eribulin with Tubulin

21 January 2018

1 reference

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

21 January 2018

1 reference

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

21 January 2018

1 reference

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

21 January 2018

1 reference

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.

21 January 2018

1 reference

Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility

21 January 2018

1 reference

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

21 January 2018

1 reference

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

21 January 2018

1 reference

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.

21 January 2018

1 reference

Eribulin -- a review of preclinical and clinical studies.

21 January 2018

1 reference

Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice

21 January 2018

1 reference

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

21 January 2018

1 reference

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

21 January 2018

1 reference

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q636

1 reference

27 August 2017

1 reference